MahindraManulife Banking & Financial Services Fund vs Nippon India Pharma Fund
Direct Plan, Growth option · Data as on 30-10-2026
MahindraManulife Banking & Financial Services Fund is a Sectoral fund and Nippon India Pharma Fund is a Sectoral fund. In the year to 30-10-2026, MahindraManulife Banking & Financial Services Fund (Direct) returned −3.3% and Nippon India Pharma Fund (Direct) returned 9.1%. MahindraManulife Banking & Financial Services Fund charges 1.13% a year and Nippon India Pharma Fund 0.99% (Direct plans). Their portfolios overlap 0.0%: they hold 0 of the same securities.
MahindraManulife Banking & Financial Services Fund
Sectoral
- 1 year return
- −3.3%
- Expense ratio
- 1.13%
- NAV
- ₹10.16
Nippon India Pharma Fund
Sectoral
- 1 year return
- 9.1%
- Expense ratio
- 0.99%
- NAV
- ₹625.46
Which is better, MahindraManulife Banking & Financial Services or Nippon India Pharma? Key differences
It depends on what you want from the fund. These are the differences in numbers, from the data on this page.
- Nippon India Pharma returned more over 1 year: 9.1% against −3.3%.
- Nippon India Pharma costs less: 0.99% a year against 1.13% (Direct plans).
- Nippon India Pharma fell less in its worst fall since 21-07-2025: −9.8% against −15.7%.
- MahindraManulife Banking & Financial Services holds more in large companies: 56.2% of the fund in large caps against 29.7%.
- Nippon India Pharma is the larger fund: ₹9,166 Cr against ₹445 Cr.
- Their portfolios overlap 0.0%: 0 of the same holdings.
Past returns do not promise future returns. This page is information, not investment advice.
Key facts
From each fund's scheme summary document and AMFI
| Fact | MahindraManulife Banking & Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Fund house | Mahindra Manulife Mutual Fund | Nippon India Mutual Fund |
| Category | Sectoral | Sectoral |
| AUM | ₹445 Cr (30-09-2026) | ₹9,166 Cr (30-09-2026) |
| NAV | ₹10.16 (Direct) | ₹625.46 (Direct) |
| Expense ratio (Direct) | 1.13% | 0.99% |
| Expense ratio (Regular) | 2.77% | 1.85% |
| Riskometer | Very High | Very High |
| Benchmark | Nifty Financial Services TRI | BSE Healthcare TRI |
| Launch date | 18-07-2025 | 05-06-2004 |
| Minimum investment | ₹1,000 | ₹5,000 |
| Lock in | None | None |
| Fund managers | Vishal Jajoo, Chetan Sanjay Gindodia | Sailesh Raj Bhan |
| Exit load | Exit Load (as % of NAV) #: -An Exit Load of 0.5% is payable if Units are redeemed / switched-out up to 3 months from the date of allotment; - Nil if Units are redeemed / switched-out after 3 months from the date of allotment. Redemption /Switch-Out of Units would be done on First in First out Basis (FIFO). # Applicable for normal subscriptions / redemptions including transactions under special products such as SIP, SWP, switches, etc. offered by the AMC. For detailed load structure disclosure, please refer SID. | Exit load of 1% if redeemed within 1 month. |
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Returns Comparison
Returns as on 30-10-2026. Up to one year they are absolute returns. Longer periods are a rate per year.
| Fund | 1M | 3M | 6M | 1Y | 3Y | 5Y | 10Y |
|---|---|---|---|---|---|---|---|
| MahindraManulife Banking & Financial Services Fund (Direct) | −2.34% | −6.10% | −2.50% | −3.33% | -- | -- | -- |
| Nippon India Pharma Fund (Direct) | −0.76% | −2.52% | +7.84% | +9.05% | +18.56% | +14.19% | +15.18% |
| Sectoral average | −1.70% | −4.49% | +2.30% | −0.58% | +15.61% | +14.51% | +14.77% |
Category average: the average of the 20 Sectoral funds, same plan type.
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Year-wise Returns
| Year | MahindraManulife Banking & Financial ServicesMahindraManulife Banking & Financial Services | Nippon India PharmaNippon India Pharma |
|---|---|---|
| 2026to date | −5.39% | +9.76% |
| 2025 | -- | −2.46% |
| 2024 | -- | +35.26% |
| 2023 | -- | +40.36% |
| 2022 | -- | −9.06% |
| 2021 | -- | +25.12% |
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Rolling Returns
Every holding period of both funds, against Nifty Financial Services TRI, the benchmark of MahindraManulife Banking & Financial Services Fund
Rolling returns
Every 1-year holding period, 70 of them, one for each trading day from 21-07-2026 to 30-10-2026: the yearly return (CAGR) of each, plotted on the day it ended. One lucky or unlucky start day cannot flatter or hide a fund.
MahindraManulife Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
to
Jul 2026Aug 2025
to
Aug 2026Sept 2025
to
Sept 2026Sept 2025
to
Sept 2026Oct 2025
to
Oct 2026Oct 2025
to
Oct 2026
How the periods spread
| Fund | Below 0% | 0-5% | 5-10% | 10-15% | 15-20% | 20-25% | Above 25% | Mean | Median | Lowest | Highest | Beat benchmark |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MahindraManulife Banking & Financial Services | 10.0 | 18.6 | 25.7 | 40.0 | 5.7 | 0.0 | 0.0 | 8.0% | 8.8% | −4.6% | 17.4% | 100% |
| Nippon India Pharma | 0.0 | 5.8 | 30.4 | 59.4 | 4.3 | 0.0 | 0.0 | 10.5% | 10.7% | 2.6% | 15.4% | 100% |
| Nifty Financial Services TRI | 67.1 | 32.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −2.4% | −1.6% | −10.9% | 3.8% | -- |
The table shows the % of periods in each return band; a darker cell holds more of them. Lumpsum: the yearly rate (CAGR) from a period's first NAV to its last. SIP: the XIRR of the monthly instalments. The benchmark is Nifty Financial Services TRI, over the same periods. "Beat benchmark" counts the periods in which the fund did better. Every fund is measured over the days all of them have, from 21-07-2025. Past returns do not promise future returns.
MahindraManulife Banking & Financial Services vs Nippon India Pharma: SIP and Lumpsum Returns
What the same monthly or one-time investment would be worth in each fund today, from their own NAV history
Growth of an investment
₹10,000 on the first trading day of every month, from 21-07-2025 to 30-10-2026: 16 instalments, ₹1,60,000 in all.
| Investment | Invested | Value now | Gain | Return a year |
|---|---|---|---|---|
| MahindraManulife Banking & Financial ServicesMahindraManulife Banking & Financial Services Fund (Direct) | ₹1,60,000 | ₹1,56,250 | −₹3,750 | −3.3% |
| Nippon India PharmaNippon India Pharma Fund (Direct) | ₹1,60,000 | ₹1,70,919 | ₹10,919 | 9.8% |
MahindraManulife Banking & Financial ServicesMahindraManulife Banking & Financial Services Fund (Direct)
Nippon India PharmaNippon India Pharma Fund (Direct)
Amount invested
From each plan's published NAV (Growth option), over the same days. Return a year: XIRR for a SIP, CAGR for a lumpsum, shown for a year or more. It does not include exit load, stamp duty or tax. Past returns do not promise future returns.
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Risk and Drawdowns
How much each fund swings, and the worst fall over the same days
Risk and return
| Measure | MahindraManulife Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | −3.33% | +9.05% |
| Standard deviation | 18.14% | 12.27% |
| Sharpe ratio | -0.47 | 0.31 |
| Sortino ratio | -0.65 | 0.45 |
| Maximum drawdown | −15.7% (31-03-2026) | −9.6% (23-10-2026) |
| Beta | 1.00 | 0.87 |
| Alpha | +5.54% | −2.40% |
From daily NAVs, 30-10-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
| Measure | MahindraManulife Banking & Financial Services Fund (Direct) | Nippon India Pharma Fund (Direct) |
|---|---|---|
| Return (CAGR) | +1.19% | +17.18% |
| Standard deviation | 16.54% | 15.19% |
| Sharpe ratio | -0.25 | 0.73 |
| Sortino ratio | -0.34 | 1.06 |
| Maximum drawdown | −15.7% (31-03-2026) | −24.0% (29-05-2017) |
| Beta | 0.99 | 0.85 |
| Alpha | +6.78% | +3.72% |
From daily NAVs, 21-07-2025 to 30-10-2026. Standard deviation: how much the daily value swings, scaled to a year. Sharpe: return above the risk-free rate (NSE's overnight rate index) per unit of swing. Sortino: the same, counting only the falls. Beta and alpha compare each fund with its own benchmark's TRI.
Drawdowns
How far below its previous high each one was on every day: the falls an investor had to sit through. 0% means it was at a new high.
MahindraManulife Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
| Fund | Worst fall | High before it | Bottom | Back at the high | Time to climb back | Below its high today |
|---|---|---|---|---|---|---|
| MahindraManulife Banking & Financial Services Fund (Direct) | −15.7% | 26-02-2026 | 31-03-2026 | 21-08-2026 | 5 months | −9.8% |
| Nippon India Pharma Fund (Direct) | −9.8% | 30-07-2025 | 29-01-2026 | 06-05-2026 | 3 months | −4.3% |
| Nifty Financial Services TRI | −17.3% | 18-02-2026 | 30-03-2026 | Not yet | -- | −12.4% |
From daily values since 21-07-2025, the first day every fund has.
Rolling standard deviation
Whether the swings have grown or calmed over time: the standard deviation of daily changes over every 1-year window, scaled to a year, plotted on the window's last day. Higher means a bumpier ride.
MahindraManulife Banking & Financial Services Fund (Direct)
Nippon India Pharma Fund (Direct)
Nifty Financial Services TRI
Against Nifty Financial Services TRI
| Fund | Up capture | Down capture | Tracking error |
|---|---|---|---|
| MahindraManulife Banking & Financial Services Fund (Direct) | 103% | 73% | 5.22% |
| Nippon India Pharma Fund (Direct) | 79% | 46% | 13.20% |
From month-end values since 21-07-2025. Up capture: a fund's average month when the benchmark rose, as % of the benchmark's; above 100% it gained more. Down capture: the same for months the benchmark fell; below 100% it fell less. Tracking error: how far the monthly returns strayed from the benchmark's, a year; an index fund aims near 0.
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Portfolio Overlap
From each fund's latest monthly portfolio: MahindraManulife Banking & Financial Services Fund, September 2026; Nippon India Pharma Fund, September 2026
Holdings in common
- Overlap
- 0.0%
- Held by both
- 0
- Only in MahindraManulife Banking & Financial Services
- 31
- Only in Nippon India Pharma
- 36
Overlap: for each holding both funds own, the smaller of its two weights, added up. 0.0% means 0.0% of each fund's money sits in positions the other also holds. Matched by ISIN. Cash and hedged positions are left out.
Largest holdings only in MahindraManulife Banking & Financial Services Fund
| Security | % of fund |
|---|---|
| ICICI Bank Limited | 11.88% |
| HDFC Bank Limited | 10.18% |
| Axis Bank Limited | 7.50% |
| State Bank of India | 5.39% |
| Multi Commodity Exchange of India Limited | 4.95% |
Largest holdings only in Nippon India Pharma Fund
| Security | % of fund |
|---|---|
| Sun Pharmaceutical Industries Limited | 11.71% |
| Divi's Laboratories Limited | 7.10% |
| Lupin Limited | 6.17% |
| Cipla Limited | 6.01% |
| Dr. Reddy's Laboratories Limited | 5.45% |
Asset and sector split
Share of each fund, from its latest monthly portfolio
Asset allocation
| Asset | MahindraManulife Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Equity | 97.5% | 97.3% |
| Debt | 0.0% | 0.0% |
| Cash and others | 2.5% | 2.7% |
Market cap of stocks
| Market cap | MahindraManulife Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Large Cap | 56.2% | 29.7% |
| Mid Cap | 26.8% | 39.0% |
| Small Cap | 13.5% | 28.0% |
| Not on AMFI's list | 1.0% | 0.5% |
Share of the whole fund. Groups follow AMFI's latest list: Large Cap is the 100 largest companies, Mid Cap the next 150, Small Cap the rest.
Largest sectors
| Sector | MahindraManulife Banking & Financial Services | Nippon India Pharma |
|---|---|---|
| Pharmaceuticals & Biotechnology | 0.0% | 74.0% |
| Banks | 54.3% | 0.0% |
| Healthcare Services | 0.0% | 20.3% |
| Finance | 19.8% | 0.0% |
| Capital Markets | 12.9% | 0.0% |
| Insurance | 5.5% | 0.0% |
| Financial Technology (Fintech) | 5.0% | 0.0% |
| Retailing | 0.0% | 2.5% |
| Healthcare Equipment & Supplies | 0.0% | 0.5% |
The six largest sectors of each fund's stocks, % of the fund.
MahindraManulife Banking & Financial Services vs Nippon India Pharma: Expense Ratio
What each plan charges a year, from AMFI's expense ratio file
| Charge | MahindraManulife Banking & Financial Services Fund | Nippon India Pharma Fund |
|---|---|---|
| Total expense ratio (Direct) | 1.13% | 0.99% |
| Base expense ratio (Direct) | 0.65% | 0.79% |
| Total expense ratio (Regular) | 2.77% | 1.85% |
| Base expense ratio (Regular) | 2.10% | 1.52% |
The expense ratio comes out of the fund's assets every day, so every return on this page is already after it. Base expense ratio: the fund house's own fee. The total adds brokerage, transaction costs, and levies with GST.
More comparisons
Each fund against the others of its category
Compare MahindraManulife Banking & Financial Services with
- MahindraManulife Banking & Financial Services vs DSP Healthcare
- MahindraManulife Banking & Financial Services vs Bandhan Transportation and Logistics
- MahindraManulife Banking & Financial Services vs Nippon India Power & Infra
- MahindraManulife Banking & Financial Services vs Invesco India Financial Services
MahindraManulife Banking & Financial Services Fund vs Nippon India Pharma Fund: Frequently Asked Questions
What is the difference between MahindraManulife Banking & Financial Services Fund and Nippon India Pharma Fund?
MahindraManulife Banking & Financial Services Fund is a Sectoral fund, Nippon India Pharma Fund is a Sectoral fund, run by Mahindra Manulife Mutual Fund and Nippon India Mutual Fund. Their portfolios overlap 0.0%. MahindraManulife Banking & Financial Services Fund charges 1.13% a year and Nippon India Pharma Fund 0.99%.
Which has given higher returns, MahindraManulife Banking & Financial Services Fund or Nippon India Pharma Fund?
Over 1 year: MahindraManulife Banking & Financial Services Fund −3.33%, Nippon India Pharma Fund +9.05%. As on 30-10-2026. Past returns do not promise future returns.
Which has the lower expense ratio, MahindraManulife Banking & Financial Services Fund or Nippon India Pharma Fund?
Nippon India Pharma Fund charges less: 0.99% a year against 1.13%. These are the Direct plans' total expense ratios reported to AMFI.
How much do MahindraManulife Banking & Financial Services Fund and Nippon India Pharma Fund overlap?
0.0%. They hold 0 of the same securities. From each fund's latest monthly portfolio.
Which is riskier, MahindraManulife Banking & Financial Services Fund or Nippon India Pharma Fund?
On SEBI's riskometer, MahindraManulife Banking & Financial Services Fund is rated Very High and Nippon India Pharma Fund Very High. Over 1 years, the standard deviation of daily returns was 18.14% and 12.27% a year.
Can I invest in both MahindraManulife Banking & Financial Services Fund and Nippon India Pharma Fund?
Yes. 0.0% of each fund's money sits in the same holdings, so the two hold mostly different investments.
Who manages MahindraManulife Banking & Financial Services Fund and Nippon India Pharma Fund?
MahindraManulife Banking & Financial Services Fund: Vishal Jajoo, Chetan Sanjay Gindodia. Nippon India Pharma Fund: Sailesh Raj Bhan.
Sources: NAV and expense ratio from AMFI. Holdings from each fund house's monthly portfolio statement. Fund facts from each scheme summary document.
This page is information, not investment advice. Mutual fund investments are subject to market risks; read all scheme related documents carefully. Past returns do not promise future returns. Figures come from AMFI, NSE, BSE and each fund house's own documents.